Minutes from Xbrane Biopharma AB’s (publ) Annual General Meeting

Press release
2017-05-22

The shareholders of Xbrane Biopharma AB (publ) gathered in Stockholm, Sweden, 18 May 2017 for the Annual General Meeting.

The consolidated income statements and balance sheets were approved and the Board and the CEO were discharged from liability for the financial year 2016.
                   
The Annual General Meeting decided to allocate the results according to the Board's proposal in the annual report.

Saeid Esmaeilzadeh, Maris Hartmanis, Karin Wingstrand, Peter Edman, Giorgio Chirivi and Alessandro Sidoli were re-elected to the Board. Saeid Esmaeilzadeh was elected Chairman of the Board.

Remuneration to the Board for the period until next Annual General Meeting, of SEK 600,000 was proposed, of which SEK 100,000 is for the Chairman of the Board and SEK 100,000 each for the remaining members.

The registered accounting firm KPMG AB was re-elected as the auditor of the company, with authorized public accountant Duane Swanson as chief auditor. Fees to the auditor shall be paid upon approval of their invoice.

The AGM gave the Board mandate to decide on the issue of shares, warrants and / or convertibles, with or without preferential rights for shareholders, to be paid in cash, by property or by way of set-off, until the next Annual General Meeting on one or more occasions. The authorization can not be used to increase the company's number of shares with more than 2,000,000 shares.

Finally, the AGM approved the Board's proposal of issue a total of 16,500 new shares to quote value to employees as a part of remuneration program for 2016.

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com